Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 142

1.

Effectiveness, safety, and methotrexate dose-tapering pattern over two years of treatment with adalimumab and ≥12 mg/week methotrexate for early rheumatoid arthritis: Results of the HAWK postmarketing surveillance study in Japan.

Tanaka Y, Mimori T, Yamanaka H, Sunaga N, Morita K, Kimura J, Takeuchi T.

Mod Rheumatol. 2019 Jul 22:1-10. doi: 10.1080/14397595.2019.1639931. [Epub ahead of print]

PMID:
31267801
2.

An Exploratory Randomized Phase II Trial Comparing CDDP Plus S-1 With Bevacizumab and CDDP Plus Pemetrexed With Bevacizumab Against Patients With Advanced Non-squamous Non-small Cell Lung Cancer.

Kaira K, Imai H, Souma R, Sakurai R, Miura Y, Sunaga N, Kasahara N, Tsukagoshi Y, Koga Y, Kitahara S, Kotake M, Minato K, Naruse I, Fukushima Y, Hisada T, Ishizuka T.

Anticancer Res. 2019 May;39(5):2483-2491. doi: 10.21873/anticanres.13368.

PMID:
31092443
3.

Dual inhibition of MEK and p38 impairs tumor growth in KRAS-mutated non-small cell lung cancer.

Sunaga N, Miura Y, Tsukagoshi Y, Kasahara N, Masuda T, Sakurai R, Kaira K, Hisada T.

Oncol Lett. 2019 Mar;17(3):3569-3575. doi: 10.3892/ol.2019.10009. Epub 2019 Feb 4.

4.

Post-treatment Glasgow Prognostic Score Predicts Efficacy in Advanced Non-small-cell Lung Cancer Treated With Anti-PD1.

Kasahara N, Sunaga N, Tsukagoshi Y, Miura Y, Sakurai R, Kitahara S, Yokobori T, Kaira K, Mogi A, Maeno T, Asao T, Hisada T.

Anticancer Res. 2019 Mar;39(3):1455-1461. doi: 10.21873/anticanres.13262.

PMID:
30842182
5.

Concurrent development of psoriatic arthritis, drug-induced interstitial pneumonia, and increased anti-nuclear antibodies in a patient with psoriasis vulgaris undergoing adalimumab treatment.

Yasuda M, Morimoto N, Yonemoto Y, Sunaga N, Ishikawa O.

Eur J Dermatol. 2019 Feb 1;29(1):81-82. doi: 10.1684/ejd.2018.3434. No abstract available.

PMID:
30530442
6.

Phase I dose escalation study of pemetrexed and concurrent thoracic radiation in elderly patients with non-squamous non-small-cell lung cancer.

Kaira K, Ono A, Kamide Y, Sunaga N, Koga Y, Saitoh JI, Shirai K, Ebara T, Hisada T, Ishizuka T.

J Radiat Res. 2019 Mar 1;60(2):228-233. doi: 10.1093/jrr/rry058.

7.

Small Cell Lung Cancer with Sarcoidosis in Spontaneous Remission: A Case Report.

Sasaki Y, Koga Y, Kasahara N, Hachisu Y, Murata K, Tsurumaki H, Yatomi M, Tsukagoshi Y, Sawada Y, Sakurai R, Ono A, Sunaga N, Kaira K, Hirato J, Maeno T, Dobashi K, Hisada T.

J Nippon Med Sch. 2018;85(5):291-296. doi: 10.1272/jnms.JNMS.2018_85-47. Review.

8.

[The Incidence and Management of Hypersensitivity and Infusion Reactions in an Outpatient Chemotherapy Center].

Sekine H, Akaiwa A, Onozawa Y, Kinjo T, Nakamura H, Nakamura R, Nawa M, Yoshida S, Araki N, Iizuka M, Shimizu H, Sunaga N, Tsukamoto N.

Gan To Kagaku Ryoho. 2018 Nov;45(11):1625-1629. Japanese.

PMID:
30449851
9.

Role of Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer.

Miura Y, Sunaga N.

Cancers (Basel). 2018 Jul 27;10(8). pii: E245. doi: 10.3390/cancers10080245. Review.

10.

Correlation of tumor-related immunity with 18F-FDG-PET in pulmonary squamous-cell carcinoma.

Kasahara N, Kaira K, Bao P, Higuchi T, Arisaka Y, Erkhem-Ochir B, Sunaga N, Ohtaki Y, Yajima T, Kosaka T, Oyama T, Yokobori T, Asao T, Nishiyama M, Tsushima Y, Kuwano H, Shimizu K, Mogi A.

Lung Cancer. 2018 May;119:71-77. doi: 10.1016/j.lungcan.2018.03.001. Epub 2018 Mar 16.

PMID:
29656756
11.

The effect of post-progression survival on overall survival among patients with sensitive relapse of small cell lung cancer.

Miura Y, Imai H, Sakurai R, Kaira K, Sunaga N, Minato K, Saito R, Hisada T.

Med Oncol. 2018 Mar 5;35(4):45. doi: 10.1007/s12032-018-1107-6.

PMID:
29508094
12.

High expression of topoisomerase-II predicts favorable clinical outcomes in patients with relapsed small cell lung cancers receiving amrubicin.

Miura Y, Kaira K, Sakurai R, Sunaga N, Saito R, Hisada T, Yamada M.

Lung Cancer. 2018 Jan;115:42-48. doi: 10.1016/j.lungcan.2017.11.010. Epub 2017 Nov 13.

PMID:
29290260
13.

A phase II study of biweekly gemcitabine and carboplatin in completely resected stage IB-IIIA non-small cell lung cancer.

Sakurai R, Tomizawa Y, Yoshii A, Miura Y, Tsurumaki H, Kaira K, Sunaga N, Kawashima O, Hisada T, Yamada M, Saito R.

Cancer Chemother Pharmacol. 2018 Jan;81(1):103-109. doi: 10.1007/s00280-017-3439-x. Epub 2017 Nov 9.

PMID:
29124327
14.

The Onset of Eosinophilic Pneumonia Preceding Anti-synthetase Syndrome.

Hachisu Y, Koga Y, Sunaga N, Kashiwagi C, Sawada Y, Saito Y, Tsukagoshi Y, Kasahara N, Sakurai R, Tsurumaki H, Yatomi M, Kaira K, Ono A, Maeno T, Hisada T.

Intern Med. 2018 Jan 15;57(2):247-251. doi: 10.2169/internalmedicine.8955-17. Epub 2017 Nov 1.

15.

Isoniazid-induced Pure Red Cell Aplasia in a Patient with Sarcoidosis: A Patient Summary and Review of the Literature.

Saito Y, Sawada Y, Koga Y, Sunaga N, Tsukagoshi Y, Hachisu Y, Osaki T, Sakurai R, Kaira K, Ono A, Sato K, Koiso H, Oyama T, Hisada T, Yamada M.

Intern Med. 2017 Oct 15;56(20):2753-2757. doi: 10.2169/internalmedicine.8379-16. Epub 2017 Sep 15.

16.

Metabolic activity by 18F-FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC.

Kaira K, Higuchi T, Naruse I, Arisaka Y, Tokue A, Altan B, Suda S, Mogi A, Shimizu K, Sunaga N, Hisada T, Kitano S, Obinata H, Yokobori T, Mori K, Nishiyama M, Tsushima Y, Asao T.

Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):56-66. doi: 10.1007/s00259-017-3806-1. Epub 2017 Aug 21.

PMID:
28828507
17.

Prognostic effect of class III β-tubulin and Topoisomerase-II in patients with advanced thymic carcinoma who received combination chemotherapy, including taxanes or topoisomerase-II inhibitors.

Miura Y, Kaira K, Sakurai R, Imai H, Tomizawa Y, Sunaga N, Minato K, Hisada T, Oyama T, Yamada M.

Oncol Lett. 2017 Aug;14(2):2369-2378. doi: 10.3892/ol.2017.6419. Epub 2017 Jun 19.

18.

Prospective exploratory study of gemcitabine and S-1 against elderly patients with advanced non-small cell lung cancer.

Kaira K, Yanagitani N, Sunaga N, Imai H, Ono A, Koga Y, Hisada T, Ishizuka T, Yamada M.

Oncol Lett. 2017 Jul;14(1):1123-1128. doi: 10.3892/ol.2017.6259. Epub 2017 May 26.

19.

High expression of GRP78/BiP as a novel predictor of favorable outcomes in patients with advanced thymic carcinoma.

Miura Y, Kaira K, Sakurai R, Imai H, Tomizawa Y, Sunaga N, Minato K, Hisada T, Oyama T, Yamada M.

Int J Clin Oncol. 2017 Oct;22(5):872-879. doi: 10.1007/s10147-017-1142-x. Epub 2017 May 26.

PMID:
28550415
20.

A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer.

Yoshioka H, Katakami N, Okamoto H, Iwamoto Y, Seto T, Takahashi T, Sunaga N, Kudoh S, Chikamori K, Harada M, Tanaka H, Saito H, Saka H, Takeda K, Nogami N, Masuda N, Harada T, Kitagawa H, Horio H, Yamanaka T, Fukuoka M, Yamamoto N, Nakagawa K.

Ann Oncol. 2017 Feb 1;28(2):285-291. doi: 10.1093/annonc/mdw621.

PMID:
28426104
21.

Evaluation of gefitinib efficacy according to body mass index, body surface area, and body weight in patients with EGFR-mutated advanced non-small cell lung cancer.

Imai H, Kuwako T, Kaira K, Masuda T, Miura Y, Seki K, Sakurai R, Utsugi M, Shimizu K, Sunaga N, Tomizawa Y, Ishihara S, Ishizuka T, Mogi A, Hisada T, Minato K, Takise A, Saito R, Yamada M.

Cancer Chemother Pharmacol. 2017 Mar;79(3):497-505. doi: 10.1007/s00280-016-3232-2. Epub 2017 Feb 6.

22.

Phase I study of nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in patients with locally advanced non-small cell lung cancer.

Kaira K, Tomizawa Y, Imai H, Sakurai R, Matsuura M, Yoshii A, Ochiai M, Kotake M, Ebara T, Saitoh JI, Sunaga N, Minato K, Saito R, Hisada T.

Cancer Chemother Pharmacol. 2017 Jan;79(1):165-171. doi: 10.1007/s00280-016-3217-1. Epub 2016 Dec 19.

PMID:
27995307
23.

Usefulness of 18F-α-Methyltyrosine PET for Therapeutic Monitoring of Patients with Advanced Lung Cancer.

Kaira K, Higuchi T, Sunaga N, Arisaka Y, Hisada T, Tominaga H, Oriuchi N, Asao T, Tsushima Y, Yamada M.

Anticancer Res. 2016 Dec;36(12):6481-6490.

PMID:
27919971
24.

Hydroxyurea-induced Pneumonitis in a Patient with Chronic Myelomonocytic Leukemia: An Autopsy Case.

Imai H, Matsumura N, Yamazaki Y, Kanayama Y, Masuda T, Kuwako T, Kamide Y, Tomizawa T, Matsumoto S, Mitsui T, Kaira K, Ono A, Koga Y, Shibusawa N, Sunaga N, Hisada T, Yokoo H, Yamada M.

Intern Med. 2015;54(24):3171-6. doi: 10.2169/internalmedicine.54.5069. Epub 2015 Dec 15.

25.

17(R)-resolvin D1 ameliorates bleomycin-induced pulmonary fibrosis in mice.

Yatomi M, Hisada T, Ishizuka T, Koga Y, Ono A, Kamide Y, Seki K, Aoki-Saito H, Tsurumaki H, Sunaga N, Kaira K, Dobashi K, Yamada M, Okajima F.

Physiol Rep. 2015 Dec;3(12). pii: e12628. doi: 10.14814/phy2.12628.

26.

Anaplastic Lymphoma Kinase (ALK) Rearrangement-positive Lung Cancer with Transformation to Pleomorphic Carcinoma.

Kamide Y, Kaira K, Watanabe T, Kuribayashi S, Ozawa A, Koga Y, Ono A, Sunaga N, Hisada T, Oyama T, Yamada M.

Intern Med. 2015;54(22):2905-9. doi: 10.2169/internalmedicine.54.4987. Epub 2015 Nov 15.

27.

Epiregulin as a therapeutic target in non-small-cell lung cancer.

Sunaga N, Kaira K.

Lung Cancer (Auckl). 2015 Oct 12;6:91-98. doi: 10.2147/LCTT.S60427. eCollection 2015. Review.

28.

Dramatic Response of S-1 Administration to Chemorefractory Advanced Thymic Cancer.

Kaira K, Naruse I, Imai H, Sunaga N, Hisada T, Motegi M, Asao T, Yamada M.

Chemotherapy. 2014;60(5-6):356-9. doi: 10.1159/000437289. Epub 2015 Sep 22.

PMID:
26389778
29.

Phase I dose escalation study of amrubicin plus paclitaxel in previously treated advanced non-small cell lung cancer.

Kaira K, Sunaga N, Imai H, Kamide Y, Koga Y, Ono A, Kuwako T, Masuda T, Hisada T, Ishizuka T, Yamada M.

Int J Clin Oncol. 2016 Apr;21(2):240-247. doi: 10.1007/s10147-015-0883-7. Epub 2015 Aug 13.

PMID:
26266640
30.

First-line gefitinib treatment in elderly patients (aged ≥75 years) with non-small cell lung cancer harboring EGFR mutations.

Kuwako T, Imai H, Masuda T, Miura Y, Seki K, Yoshino R, Kaira K, Utsugi M, Shimizu K, Sunaga N, Tomizawa Y, Ishihara S, Ishizuka T, Mogi A, Hisada T, Minato K, Takise A, Saito R, Yamada M.

Cancer Chemother Pharmacol. 2015 Oct;76(4):761-9. doi: 10.1007/s00280-015-2841-5. Epub 2015 Aug 8.

PMID:
26254024
31.

Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations.

Masuda T, Imai H, Kuwako T, Miura Y, Yoshino R, Kaira K, Shimizu K, Sunaga N, Tomizawa Y, Ishihara S, Mogi A, Hisada T, Minato K, Takise A, Saito R, Yamada M.

Clin Transl Oncol. 2015 Sep;17(9):702-9. doi: 10.1007/s12094-015-1297-8. Epub 2015 May 20.

PMID:
25990507
32.

Single-nucleotide polymorphism (c.309T>G) in the MDM2 gene and lung cancer risk.

Enokida Y, Shimizu K, Kakegawa S, Atsumi J, Takase Y, Miyamae Y, Nagashima T, Ohtaki Y, Kaira K, Sunaga N, Yanagitani N, Yoshino R, Tsunekawa K, Igai H, Kamiyoshihara M, Usui K, Lezhava A, Tomizawa Y, Ishikawa T, Murakami M, Hayashizaki Y, Takeyoshi I.

Biomed Rep. 2014 Sep;2(5):719-724. Epub 2014 Jun 26.

33.

Acidic pH increases cGMP accumulation through the OGR1/phospholipase C/Ca(2+)/neuronal NOS pathway in N1E-115 neuronal cells.

Kotake M, Sato K, Mogi C, Tobo M, Aoki H, Ishizuka T, Sunaga N, Imai H, Kaira K, Hisada T, Yamada M, Okajima F.

Cell Signal. 2014 Nov;26(11):2326-32. doi: 10.1016/j.cellsig.2014.07.010. Epub 2014 Jul 12.

PMID:
25025574
34.

Safety and efficacy of high-dose leukocytapheresis in patients with refractory asthma.

Ishizuka T, Hisada T, Hatori M, Koike A, Hanabuchi K, Matsuzaki S, Kamide Y, Utsugi M, Aoki H, Yoshino R, Yanagitani N, Koga Y, Ono A, Kaira K, Sunaga N, Dobashi K, Tsuburai T, Akiyama K, Yamada M, Suzuki K, Mori M.

Inflamm Res. 2014 Sep;63(9):789-96. doi: 10.1007/s00011-014-0753-1. Epub 2014 Jul 8.

PMID:
25001341
35.

Clinicopathological significance of ASC amino acid transporter-2 expression in pancreatic ductal carcinoma.

Kaira K, Sunose Y, Arakawa K, Sunaga N, Shimizu K, Tominaga H, Oriuchi N, Nagamori S, Kanai Y, Oyama T, Takeyoshi I.

Histopathology. 2015 Jan;66(2):234-43. doi: 10.1111/his.12464. Epub 2014 Dec 23.

PMID:
24845232
36.

Small-cell lung cancer with voltage-gated calcium channel antibody-positive paraneoplastic limbic encephalitis: a case report.

Kaira K, Okamura T, Takahashi H, Horiguchi N, Sunaga N, Hisada T, Yamada M.

J Med Case Rep. 2014 Apr 8;8:119. doi: 10.1186/1752-1947-8-119.

37.

Postrecurrence survival of surgically resected pulmonary adenocarcinoma patients according to EGFR and KRAS mutation status.

Ohtaki Y, Shimizu K, Kakegawa S, Nagashima T, Nakano T, Atsumi J, Enokida Y, Igai H, Ibe T, Sugano M, Kamiyoshihara M, Kawashima O, Kaira K, Sunaga N, Takeyoshi I.

Mol Clin Oncol. 2014 Mar;2(2):187-196. Epub 2013 Dec 31.

38.

ASC amino-acid transporter 2 (ASCT2) as a novel prognostic marker in non-small cell lung cancer.

Shimizu K, Kaira K, Tomizawa Y, Sunaga N, Kawashima O, Oriuchi N, Tominaga H, Nagamori S, Kanai Y, Yamada M, Oyama T, Takeyoshi I.

Br J Cancer. 2014 Apr 15;110(8):2030-9. doi: 10.1038/bjc.2014.88. Epub 2014 Mar 6.

39.

Clinicopathological and prognostic significance of interleukin-8 expression and its relationship to KRAS mutation in lung adenocarcinoma.

Sunaga N, Kaira K, Tomizawa Y, Shimizu K, Imai H, Takahashi G, Kakegawa S, Ohtaki Y, Nagashima T, Kasahara N, Kawashima O, Hisada T, Saito R, Yamada M.

Br J Cancer. 2014 Apr 15;110(8):2047-53. doi: 10.1038/bjc.2014.110. Epub 2014 Feb 27.

40.

Clinical significance of L-type amino acid transporter 1 expression as a prognostic marker and potential of new targeting therapy in biliary tract cancer.

Kaira K, Sunose Y, Ohshima Y, Ishioka NS, Arakawa K, Ogawa T, Sunaga N, Shimizu K, Tominaga H, Oriuchi N, Itoh H, Nagamori S, Kanai Y, Yamaguchi A, Segawa A, Ide M, Mori M, Oyama T, Takeyoshi I.

BMC Cancer. 2013 Oct 16;13:482. doi: 10.1186/1471-2407-13-482.

41.

Phase II study of oral S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer.

Kaira K, Tomizawa Y, Yoshino R, Yoshii A, Matsuura M, Iwasaki Y, Koga Y, Ono A, Nishioka M, Kamide Y, Hisada T, Ishizuka T, Shirai K, Ebara T, Saitoh J, Nakano T, Sunaga N.

Lung Cancer. 2013 Dec;82(3):449-54. doi: 10.1016/j.lungcan.2013.09.004. Epub 2013 Sep 19.

PMID:
24099666
42.

Phase II study of oral S-1 plus cisplatin with bevacizumab for advanced non-squamous non-small cell lung cancer.

Kaira K, Tomizawa Y, Yoshino R, Miura Y, Yoshii A, Iwasaki Y, Koga Y, Ono A, Hisada T, Minato K, Sato K, Kazama T, Ishihara S, Kohyama K, Fueki N, Saito R, Sunaga N.

Lung Cancer. 2013 Oct;82(1):103-8. doi: 10.1016/j.lungcan.2013.07.008. Epub 2013 Aug 5.

PMID:
23927884
43.

Perfusion evaluation of lung cancer: assessment using dual-input perfusion computed tomography.

Nakano S, Gibo J, Fukushima Y, Kaira K, Sunaga N, Taketomi-Takahashi A, Tsushima Y, Mori M.

J Thorac Imaging. 2013 Jul;28(4):253-62. doi: 10.1097/RTI.0b013e318281dcee.

PMID:
23381231
44.

Gefitinib and gemcitabine coordinately inhibited the proliferation of cholangiocarcinoma cells.

Nakajima Y, Takagi H, Kakizaki S, Horiguchi N, Sato K, Sunaga N, Mori M.

Anticancer Res. 2012 Dec;32(12):5251-62.

PMID:
23225424
45.

Interaction of radiation and gefitinib on a human lung cancer cell line with mutant EGFR gene in vitro.

Sato Y, Ebara T, Sunaga N, Takahashi T, Nakano T.

Anticancer Res. 2012 Nov;32(11):4877-81.

PMID:
23155255
46.

Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.

Sunaga N, Kaira K, Imai H, Shimizu K, Nakano T, Shames DS, Girard L, Soh J, Sato M, Iwasaki Y, Ishizuka T, Gazdar AF, Minna JD, Mori M.

Oncogene. 2013 Aug 22;32(34):4034-42. doi: 10.1038/onc.2012.402. Epub 2012 Sep 10.

47.

Establishment of a human lung cancer cell line with high metastatic potential to multiple organs: gene expression associated with metastatic potential in human lung cancer.

Nakano T, Shimizu K, Kawashima O, Kamiyoshihara M, Kakegawa S, Sugano M, Ibe T, Nagashima T, Kaira K, Sunaga N, Ohtaki Y, Atsumi J, Takeyoshi I.

Oncol Rep. 2012 Nov;28(5):1727-35. doi: 10.3892/or.2012.1972. Epub 2012 Aug 21.

PMID:
22922681
48.

Prognostic significance of L-type amino-acid transporter 1 expression in surgically resected pancreatic cancer.

Kaira K, Sunose Y, Arakawa K, Ogawa T, Sunaga N, Shimizu K, Tominaga H, Oriuchi N, Itoh H, Nagamori S, Kanai Y, Segawa A, Furuya M, Mori M, Oyama T, Takeyoshi I.

Br J Cancer. 2012 Aug 7;107(4):632-8. doi: 10.1038/bjc.2012.310. Epub 2012 Jul 17.

49.

The role of [¹⁸F]fluorodeoxyglucose positron emission tomography in thymic epithelial tumors.

Kaira K, Sunaga N, Ishizuka T, Shimizu K, Yamamoto N.

Cancer Imaging. 2011 Nov 30;11:195-201. doi: 10.1102/1470-7330.2011.0028. Review.

50.

A systemic review of PET and biology in lung cancer.

Kaira K, Oriuchi N, Sunaga N, Ishizuka T, Shimizu K, Yamamoto N.

Am J Transl Res. 2011 Aug 15;3(4):383-91. Epub 2011 Jul 27.

Supplemental Content

Loading ...
Support Center